Featured Content
Interesting Myeloma Articles September 2021
Here are some interesting Myeloma journal articles and some of the most discussed on Twitter for September 2021. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to whites: a propensity-score...
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Racial Disparities Seen in US Food and Drug Administration Drug Approval Trials in Multiple Myeloma
Source: Myeloma - Hematology Advisor According to the results of a study published in Blood Advances, Black and Hispanic patients appear to be underrepresented in global clinical trials supporting US Food and Drug Administration (FDA) approval of multiple myeloma (MM)...
Sarclisa Combination Shows Positive Results in Patients With Relapsed Multiple Myeloma
Source: Pharmacy Times articles Latest results of the phase 3 IKEMA trial demonstrate the longest median progression-free survival on a proteasome inhibitor backbone in this population, Sanofi says. Read More
Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Ninlaro as Oral Combo Therapy Fails at Trial in Heavily Treated Patients
Source: Myeloma Research News – The Web's Daily Resource for Myeloma Research News Adding Ninlaro (ixazomib) to cyclophosphamide and dexamethasone does not improve progression-free survival for multiple myeloma patients who relapsed after several lines of treatment, a...
Ninlaro as Oral Combo Therapy Fails at Trial in Heavily Treated Patients
Source: Myeloma Research News – The Web's Daily Resource for Myeloma Research News Adding Ninlaro (ixazomib) to cyclophosphamide and dexamethasone does not improve progression-free survival for multiple myeloma patients who relapsed after several lines of treatment, a...
Ninlaro as Oral Combo Therapy Fails at Trial in Heavily Treated Patients
Source: Myeloma Research News – The Web's Daily Resource for Myeloma Research News Adding Ninlaro (ixazomib) to cyclophosphamide and dexamethasone does not improve progression-free survival for multiple myeloma patients who relapsed after several lines of treatment, a...
Ninlaro as Oral Combo Therapy Fails at Trial in Heavily Treated Patients
Source: Myeloma Research News – The Web's Daily Resource for Myeloma Research News Adding Ninlaro (ixazomib) to cyclophosphamide and dexamethasone does not improve progression-free survival for multiple myeloma patients who relapsed after several lines of treatment, a...
Ninlaro as Oral Combo Therapy Fails at Trial in Heavily Treated Patients
Source: Myeloma Research News – The Web's Daily Resource for Myeloma Research News Adding Ninlaro (ixazomib) to cyclophosphamide and dexamethasone does not improve progression-free survival for multiple myeloma patients who relapsed after several lines of treatment, a...
Ninlaro as Oral Combo Therapy Fails at Trial in Heavily Treated Patients
Source: Myeloma Research News – The Web's Daily Resource for Myeloma Research News Adding Ninlaro (ixazomib) to cyclophosphamide and dexamethasone does not improve progression-free survival for multiple myeloma patients who relapsed after several lines of treatment, a...
Ninlaro as Oral Combo Therapy Fails at Trial in Heavily Treated Patients
Source: Myeloma Research News – The Web's Daily Resource for Myeloma Research News Adding Ninlaro (ixazomib) to cyclophosphamide and dexamethasone does not improve progression-free survival for multiple myeloma patients who relapsed after several lines of treatment, a...
Recent Publications
The Heparanase/Syndecan-1 Axis in Cancer Progression
FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.0I190. ABSTRACT Although oncogenic mutations are considered the primary drivers of tumor initiation, latter steps in cancer progression including angiogenesis, invasion and metastasis are greatly influenced...
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma
Clin Cancer Res. 2022 May 13;28(10):2160-2166. doi: 10.1158/1078-0432.CCR-20-2995. ABSTRACT PURPOSE: Minimal residual disease (MRD) negativity is a strong predictor for outcome in multiple myeloma. To assess V(D)J clonotype capture using the updated Adaptive...
Computational and Mechanistic Study of the Therapeutic Potential of Compound Formononetin in Preventing Mast Cell Activation and IgE Production in Food Anaphylaxis
FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.R4476. ABSTRACT The prevalence of allergic diseases such as Asthma, Rhinitis, Anaphylaxis, Eczema, Urticaria, and Angioedema have been rising dramatically in low- and middle-income countries around the...
Transcriptome and regulome signatures of multiple myeloma induced by bone marrow stromal cells
FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.R6057. ABSTRACT Multiple myeloma (MM) is the second most common hematological cancer and remains incurable due to inevitable drug resistance. One contribution to drug resistance stems from the protective...
One-Year Comparison of Body Composition in a Cohort of Patients with Multiple Myeloma
FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.0R733. ABSTRACT OBJECTIVE: To examine whether there are changes in body fat composition and skeletal muscle density over a one-year period in a cohort of patients with multiple myeloma. HYPOTHESIS: We...
Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma
Int J Mol Sci. 2022 Apr 25;23(9):4717. doi: 10.3390/ijms23094717. ABSTRACT Multiple Myeloma (MM) is a devastating malignancy that evades immune destruction using multiple mechanisms. The NKp44 receptor interacts with PCNA (Proliferating Cell Nuclear Antigen) and may...
The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches
Int J Mol Sci. 2022 May 8;23(9):5242. doi: 10.3390/ijms23095242. ABSTRACT Multiple Myeloma (MM) is a malignant growth of clonal plasma cells, typically arising from asymptomatic precursor conditions, namely monoclonal gammopathy of undetermined significance (MGUS) and...
Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
Cells. 2022 May 7;11(9):1574. doi: 10.3390/cells11091574. ABSTRACT Mesenchymal stem/stromal cells (MSCs) are self-renewing and multipotent progenitors, which constitute the main cellular compartment of the bone marrow stroma. Because MSCs have an important role in the...
